Site menu

Search by ticker code:
Generic filters

Menu

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Volpara Health Technologies Ltd (ASX:VHT) share price soars on strong FY24 update

The Volpara Health Technologies Ltd (ASX: VHT) share price has jumped 6% after its latest FY24 update.

The ASX healthcare share provides software for breast cancer screening imaging, analysis, and healthcare professional workflow.

Volpara Health Technologies Ltd (ASX: VHT) share price

FY24 second quarter update

In the three months to 30 September 2023, it achieved its fourth consecutive positive net operating cash flow quarter of NZ$1.2 million, a full-year and a half ahead of guidance.

The company also said that it has been net operating cash flow positive for over 12 months since the start of October 2022, to the tune of approximately NZ$3.4 million and free cash flow positive for the same period to approximately NZ$730,000.

Revenue/cash receipts continue to soar for the company. In the second quarter, it saw cash receipts jump 32% year on year to NZ$11.5 million.

The company said it’s no longer required to provide Appendix 4C quarterly reporting updates.

Future revenue growth looks good

The company said that its contracted annual recurring revenue (CARR) has grown to US$28.4 million, or NZ$46.3 million, up US$1.2 million on the prior quarter of the FY24 first quarter.

Its annual recurring revenue (ARR) has grown to US$22.5 million, or NZ$36.6 million, up from US$21.5 million in the prior quarter.

It has won/renewed contracts with a number of clients including Memorial Sloan Kettering, Northwell Imaging, Hackensack, Avera Health, Northeast Georgia Medical Center, West Tennessee Imaging Center and more.

Management commentary

The Volpara CEO and Managing Director Teri Thomas said:

What a milestone quarter for us! I’m delighted to see current customers, happy with our software, expand their use of Volpara to save even more families from cancer. We had a record number of contracts up for renewal and customers have chosen to expand and extended their contracts with us for longer, with more software than ever before.

Our record cash receipts reflect the positive impact we have on families, as happy customers pay their bills. Our growth and financial strength, approaching US$100M TCV, allows us to turn increasingly to growth endeavours like a brand-new product, called Quiver, due out next year.

Leveraging our Analytics platform, this new product provides administrative simplification for mammography centres so they can spend more time with patients. We do good and we do it well and that is reflected in this positive quarter.

Final thoughts on the Volpara share price

I believe Volpara is one of the leading ASX growth shares in the small cap space because of its rapid revenue growth, growing cash flow, strong profit margins and global growth. I’d be happy to invest today for the long-term.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content